AMP trims position in NKTR

Yesterday AMP trimmed its position in Nektar Therapeutics by trimming 33% of its position. Buoyed by recent positive Ph1/2 results for NKTR-214 in solid tumors in combination with Opdivo, AMP's position was up ~200% at the time of the sale.


*Disclaimer: Information provided on and in any of our reports, products and services are for information only and are not investment advice. Please consult with an investment adviser and do your own diligence before making any investment decisions or taking any action.  By accessing this site, you agree to our Terms of Use and Privacy Policy that can be accessed here. Big Movers™ is a trademark of Amp Biotech Research, LLC

©2021 by Biopharm IQ. Website by Awaken Studio.